June 17, 2024
Company name:
Repres entativ e:

A l i v e x i s , I n c .
S. Roy Kimura, Ph.D., CEOAlivexis with Astellas Pharma Inc. to Collaborate on Novel Drug Target

News – June 17, 2024 - Alivexis, Inc. (Headquartered in Minato-ku, Tokyo; CEO S. RoyKimura) is pleased to announce that the Company has entered into a Research Collaboration
Agreement with Astellas Pharma Inc. ("Astellas") to identify small molecule compounds for a
new drug target selected by Astellas, utilizing Alivexis’ drug discovery platform ModBind™
and other technologies.

The collaboration aims to utilize Alivexis' computational drug discovery platform,
including ModBind™, to discover new small molecule compounds which will regulate thefunction of a novel drug target molecule selected by Astellas. As this target has no reported
functional modulators to-date, the collaboration will accelerate the drug discovery of novel
therapeutics against the target. In addition to in silico evaluation using the computational drug
discovery platform, Alivexis will be responsible for integrated drug discovery research,
including the development of experimental assays and compound evaluation using thoseassays. Under the terms of the collaboration, Astellas will have the option to acquire rights
to the research deliverables.
About ModBind™.
Alivexis has established a computational drug discovery platform that greatly accelerates
small molecule drug discovery, which includes physics-based molecular dynamics
simulations using GPUs (Graphics Processing Units), large-scale virtual screening
algorithms, and deep learning models. With the help of their computational drug discovery
platform, Alivexis has already delivered several clinical candidate molecules for both in-housedrug discovery projects and external collaborations. Among Alivexis’ various computational
drug discovery tools, the newly developed ModBind™ is a molecular simulations-basedalgorithm that can predict the efficacy of drug candidate compounds with high accuracy, yet
performs more than 100 times faster than the other state-of-the-art technologies in the field.
ModBind™ is based on a theoretical approach that is fundamentally different from industry
standard simulations-based prediction technologies. One significant advantage of1

ModBind™ is that it is an absolute predictor of ligand efficacy and does not require knownreference compounds, which are usually necessary for other methodologies. Therefore,
ModBind™ is useful in all stages of preclinical drug discovery – from screening large randomchemical libraries for initial hit finding to delivering clinical candidates in the lead-optimization
stage. This capability has already been proven by Alivexis’ in-house research and external
collaborations and is contributing to the progression of many drug discovery projects.

【CEO S. Roy Kimura’s Comments】“I am excited to announce the signing of our drug discovery collaboration with Astellas
focused on the use of our proprietary and ground-breaking ModBind™ simulation technology
to accelerate early drug discovery for a particular disease target. Through our collaboration,
we look forward to gaining further validation of our technology while contributing to thediscovery of novel clinical candidate compounds for diseases with high patient need.”

About Alivexis, Inc.
Name： Alivexis, Inc.
Headquarter：Daiichi Hibiya Building 7F Shimbashi 1-18-21, Minato-ku,Tokyo 105-0004, Japan
Representative directors: S. Roy Kimura, Ph.D., CEO / Kazuki Ohno, Dr. Eng. COO
Established: August 8, 2016
URL： https://alivexis.com
Business Description: A network-based drug discovery company utilizing cutting-edge
technologies.

Questions?
info@alivexis.com

2